CoFI System Learn More CoFI System Learn More What is the importance of identifying and addressing microvascular disease, and specifically microvascular obstruction in heart attack patients? What is coronary microvasculature? The coronary microcirculation plays a critical role in the heartâs blood flow regulation and is defined as vessels with a lumen diameter of
Location: Switzerland, Zug, Baar
Total raised: $48.75M
Investors 1
| Date | Name | Website |
| - | KOFA Healt... | kofahealth... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.09.2024 | Series B | $48.75M | - |
Mentions in press and media 8
| Date | Title | Description |
| 23.01.2026 | Swiss startups garner national and international recognition | TechTour Growth 50 (TTG50) Europe each year identifies the most promising tech companies across Europe with the clearest potential to achieve unicorn status. The 20th edition has just been released, featuring six Swiss scale-ups. A total o... |
| 09.07.2025 | Key milestones bring startups close to launching vital medical solutions | CorFlow Therapeutics AG, a pioneering company in the field of cardiac care targeting microvascular disease developed the Controlled Flow Infusion (CoFI) System designed for the diagnosis and treatment of microvascular obstruction (MVO), a ... |
| 12.09.2024 | CorFlow Therapeutics Secures €44 Million to Revolutionize Heart Attack Treatment | CorFlow Therapeutics is on a mission. The Swiss company has just raised €44 million in a Series B funding round, co-led by Broadview Ventures and Panakes Partners. This influx of capital is not just a financial boost; it’s a lifeline for pa... |
| 12.09.2024 | CorFlow Therapeutics raises €44 million in Series B round | Headquarted in Baar (Zug), CorFlow’s Controlled Flow Infusion (CoFI) system is being developed to provide timely, accurate and consistent detection of Microvascular Obstruction (MVO) while patients are still in the catheter laboratory (cat... |
| 12.09.2024 | CorFlow Therapeutics raises €44 million in Series B round | Co-led by Broadview Ventures and Panakes Partners, CoFlow’s series B round received strong continued support from 415 Capital, its initial VC investor and largest shareholder. Merieux Equity Partners, Laerdal Million Lives Fund, Wellington... |
| 12.09.2024 | CorFlow Therapeutics: €44 Million (Series B) Raised For Advancing Drug Delivery Platform Related To Microvascular Obstruction In Heart Attack Patients | CorFlow Therapeutics AG announced that it has raised €44 million in Series B funding, co-led by Broadview Ventures and Panakes Partners with strong continued support from 415 Capital (CorFlow’s initial VC investor and largest shareholder). ... |
| 10.09.2024 | CorFlow Therapeutics Raises €44M in Series B Funding | CorFlow Therapeutics, a Baar, Switzerland-based company advancing diagnostic and therapeutic solutions for restoring healthy microvascular blood flow, raised €44M in Seris B funding. The round was co-led by Broadview Ventures and Panakes Pa... |
| - | CorFlow | “CoFI System Learn More CoFI System Learn More What is the importance of identifying and addressing microvascular disease, and specifically microvascular obstruction in heart attack patients? What is coronary microvasculature? The coronary ... |